(Q39707468)

14 September 2017

Identification of biomarkers in human head and neck tumor cell lines that predict for in vitro sensitivity to gefitinib (English)

1 reference

14 September 2017

0 references

head and neck neoplasms

1 reference

inferred from title

author

Marileila Varella-Garcia

4

object named as

Marileila Varella-Garcia

1 reference

14 September 2017

15

Fred R Hirsch

1 reference

14 September 2017

D Mark Hickinson

1

1 reference

14 September 2017

Gayle B Marshall

2

1 reference

14 September 2017

Garry J Beran

3

1 reference

14 September 2017

Elizabeth A Mills

5

1 reference

14 September 2017

Marie C South

6

1 reference

14 September 2017

Andrew M Cassidy

7

1 reference

14 September 2017

Kerry L Acheson

8

1 reference

14 September 2017

Gael McWalter

9

1 reference

14 September 2017

Rose M McCormack

10

1 reference

14 September 2017

Paul A Bunn

11

1 reference

14 September 2017

Tim French

12

1 reference

14 September 2017

Alex Graham

13

1 reference

14 September 2017

Brian R Holloway

14

1 reference

14 September 2017

Georgina Speake

16

1 reference

14 September 2017

language of work or name

English

0 references

publication date

1 June 2009

1 reference

Clinical and Translational Science

14 September 2017

1 reference

14 September 2017

2

1 reference

14 September 2017

3

1 reference

14 September 2017

183-192

1 reference

Gene expression profiles as biomarkers for the prediction of chemotherapy drug response in human tumour cells

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5350732

HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5350732

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5350732

Erlotinib in lung cancer - molecular and clinical predictors of outcome

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5350732

Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5350732

Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5350732

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5350732

Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5350732

Epidermal growth factor receptor: mechanisms of activation and signalling.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5350732

Epidermal growth factor receptor biology (IMC-C225).

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5350732

A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5350732

Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5350732

Prognostic significance of ERRB3 overexpression in oral squamous cell carcinoma

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5350732

Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non-small cell lung carcinoma

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5350732

Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5350732

Gefitinib-sensitizing mutation in esophageal carcinoma cell line Kyse450.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5350732

Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5350732

Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5350732

Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients

20 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5350732

Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck

20 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5350732

ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy.

20 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5350732

Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial

20 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5350732

C-erbB receptors in squamous cell carcinomas of the head and neck: clinical significance and correlation with matrix metalloproteinases and vascular endothelial growth factors.

20 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5350732

Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer

20 August 2018

1 reference

12 December 2020

Characterization, quantification, and potential clinical value of the epidermal growth factor receptor in head and neck squamous cell carcinomas

1 reference

12 December 2020

Detection of EGFR- and HER2-activating mutations in squamous cell carcinoma involving the head and neck

1 reference

12 December 2020

Expression and regulation of c-ERBB ligands in human head and neck squamous carcinoma cells

1 reference

12 December 2020

10.1111/J.1752-8062.2009.00099.X

Identifiers

DOI

1 reference

14 September 2017

1 reference

14 September 2017

PubMed publication ID

20443891

1 reference